- Revenue Performance: Virbac’s organic revenue growth increased by 4.9% in the first quarter, measured at constant exchange rates and scope.
- Total Revenue: Achieved €375.2 million in revenue for the period.
- 2025 Financial Forecast: Virbac expects organic revenue growth to continue at a rate of 4% to 6% for the full year.
- Profit Margin: The adjusted current operating income margin is projected to hold steady at approximately 16% for 2025.
- Impact of Tariffs: A moderate impact is anticipated from potential increases in U.S. customs tariffs.
- Raw Material Exposure: Limited exposure to raw materials purchased in China through the U.S., amounting to about €2 million annually.
- Sasaeah Acquisition: Expected to contribute an additional 1 percentage point of growth in 2025, with a broadly neutral effect on operating profit.
- Cash Position Improvement: Projected improvement in cash position by €80 million in 2025, not considering further acquisitions.
- Market Sentiment: Analyst recommendations include 8 buy ratings and 3 hold ratings, with no sell ratings.
A look at Virbac SA Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 4 | |
| Resilience | 4 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Virbac SA, a company specializing in manufacturing veterinary medicines like antibiotics, worm treatments, and vaccines, seems to have a promising long-term outlook based on the Smartkarma Smart Scores. With a strong Growth score of 4 and a Resilience score of 4, the company demonstrates good potential for expansion and ability to weather economic uncertainties. This indicates that Virbac SA is well-positioned to thrive and adapt in the market, showcasing stability and growth prospects.
Although the Value and Dividend scores are moderate at 2, the Momentum score of 3 suggests a steady upward trend. Overall, with a positive emphasis on growth and resilience, Virbac SA‘s outlook appears favorable for investors seeking a company with solid growth prospects and a stable market presence.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
